Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;19(4):370-370.e7.
doi: 10.1016/j.clgc.2021.01.009. Epub 2021 Feb 7.

A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma

Rebecca Shay  1 , Andrew Nicklawsky  2 , Dexiang Gao  2 , Elaine T Lam  3
Affiliations

A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma

Rebecca Shay et al. Clin Genitourin Cancer. 2021 Aug.

Abstract

Background: There now exist several viable first-line treatment options for metastatic renal cell carcinoma, making the choice of initial therapy difficult. Considering metrics other than patient factors may be necessary to select the most appropriate therapy. We aimed to assess the cost-effectiveness of the three combination therapies currently approved in treatment-naïve advanced or metastatic renal cell carcinoma-nivolumab + ipilimumab (NI), pembrolizumab + axitinib (PA), and avelumab + axitinib (AA)-from a US payer perspective.

Patients and methods: Our analysis was performed based on previously obtained data derived from progression-free survival and overall survival curves from CheckMate 214, KEYNOTE 426, and JAVELIN Renal 101.

Results: The total costs of each treatment were found to be $437,556.12 for NI, $450,597.15 for PA, and $542,882.34 for AA, with quality-adjusted life-year (QALY) values of 4.04, 3.77, and 2.95 for each combination, respectively. The incremental cost-effectiveness ratio (ICER) of NI versus PA was ($47,504.73/QALY); for NI versus AA, it was ($96,533.11/QALY); for PA versus AA, it was ($113,015.87/QALY). Net health benefit scaled against a willingness-to-pay threshold of $150,000 per QALY was positive for NI versus PA at 0.36 and versus AA at 1.79, and this index was also positive for PA versus AA at 1.43, indicating that the additional value of these therapies versus their alternatives is greater than the extra cost.

Conclusion: NI was found to be the most cost-effective treatment option compared with the other considered therapies. PA was found to be cost effective compared to AA. When patient factors such as social issues and pre-existing conditions do not dictate their first-line therapy, clinicians may use this additional information to make financially conscious choices.

Keywords: Cost–benefit analysis; Health care costs; Immunotherapy; Monoclonal antibodies; Protein tyrosine kinases.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Health States with Transitions
Figure 2
Figure 2. Tornado Diagram of A, Nivolumab + Ipilimumab Versus Avelumab + Axitinib; B, Avelumab + Axitinib Versus Pembrolizumab + AXITINIB; and C, Nivolumab + Ipilimumab Versus Pembrolizumab + Axitinib
Figure 3
Figure 3. Cost Effectiveness Acceptability Curves of A, Nivolumab + Ipilimumab Versus Avelumab + Axitinib; B, Nivolumab + Ipilimumab Versus Pembrolizumab + Axitinib; and C, Avelumab + Axitinib Versus Pembrolizumab + Axitinib
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. - PubMed
    1. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–1290. - PMC - PubMed
    1. Albiges L, Tannir N, Burotto M, et al. 711P nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy. Ann Oncol. 2020;31:S559–S560.
    1. US Food and Drug Administration. FDA approves nivolumab plus ipilimumab combination for intermediate- or poor-risk advanced renal cell carcinoma. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro.... Accessed February 22, 2021.
    1. National Comprehensive Cancer Network. NCCN Clinical Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed February 22, 2021.

Publication types